Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?
Alogliptin benzoate cost?
When will there be a generic loreev available?
When genetic tenofovir alafenamide be available in us?
Bivalirudin manufacturer?

Vanflyta+mechanism+of+action?

See the DrugPatentWatch profile for Vanflyta

Vanflyta® (vilazodone) is a newer antidepressant that combines two pharmacological actions:

What it does How it works Why it matters
Inhibits serotonin reuptake Vilazodone blocks the serotonin transporter (SERT) in the presynaptic neuron, preventing serotonin from being pumped back into the cell. This keeps more serotonin available in the synaptic cleft, boosting serotonin signalling – the core mechanism of many SSRIs.
Partial agonist at 5‑HT1A receptors It binds to presynaptic 5‑HT1A autoreceptors and postsynaptic 5‑HT1A receptors. At presynaptic sites it partially activates the receptor, which reduces the negative feedback that normally limits serotonin release. By lifting this brake, more serotonin is released into the synapse. At postsynaptic sites it mimics serotonin, further enhancing serotonergic tone.

How the two actions combine

  1. Serotonin reuptake inhibition → ↑ extracellular serotonin.
  2. 5‑HT1A partial agonism → ↓ autoreceptor‑mediated inhibition → ↑ serotonin release; also postsynaptic stimulation → enhanced mood‑modulating signals.

Because it both increases serotonin levels and boosts serotonin signalling through receptor modulation, vilazodone can produce antidepressant effects that may onset more quickly or with a different side‑effect profile than classic SSRIs.

Key pharmacology points

  • Selectivity: Vilazodone is a selective serotonin reuptake inhibitor; it does not significantly inhibit norepinephrine or dopamine transporters.
  • Receptor profile: It has modest affinity for several serotonin receptor subtypes, but the primary pharmacological actions are SERT inhibition and 5‑HT1A partial agonism.
  • Metabolism: Primarily metabolized by CYP2D6 and CYP3A4; dose adjustments may be needed with strong inhibitors or inducers of these enzymes.
  • Side‑effects: Common GI symptoms (diarrhea, nausea) are often attributed to the 5‑HT1A activity. Headache and insomnia are also reported. The 5‑HT1A partial agonism can sometimes mitigate the sexual side‑effects that are more common with pure SSRIs.

Bottom line

Vanflyta works by keeping more serotonin in the synapse (SSRI activity) and by enhancing serotonin signalling via 5‑HT1A receptors (partial agonist activity). This dual mechanism aims to improve mood while potentially offering a different side‑effect profile compared with traditional SSRIs.



Other Questions About Vanflyta :

about+vanflyta Vanflyta price? How to get vanflyta? Vanflyta pi? Vanflyta? Vanflyta administration? Vanflyta manufacturer?